Growth Hormone Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: Once daily (typically evening) Dose Range: Adults: 0.15–0.3 mg/day SC (GH deficiency); Pediatric: 0.025–0.05 mg/kg/day SC
Safety & Contraindications
Safety: Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia) Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes Fluid retention: peripheral edema, especially at treatment initiation
Contraindications: Active malignancy (cancer); Active proliferative or severe non-proliferative diabetic retinopathy; Acute critical illness (increased mortality demonstrated in ICU patients — Takala et al., NEJM 1999)
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Insulin-Like Growth Factors: IGF-1 and IGF-2 Explained
Insulin-like growth factors IGF-1 and IGF-2 play key roles in growth and development. IGF-1, stimulated by growth hormone, rises 2-3 fold during puberty and acts as both endocrine and local growth factors. IGF-2 supports fetal growth and binds distinct receptors, influencing proliferation and survival.